Imunon, Inc. — 2020 Form 10-K Summary
Entity and period: The supplied filing identifies the registrant as Celsion Corporation (ticker CLSN), not Imunon, Inc. It reports the fiscal year ended December 31, 2020; the filing does not provide a clear standalone fourth-quarter income statement or cash-flow summary.
Business context and reporting period
Celsion was a clinical-stage biotechnology company with no marketed products. Its principal programs were GEN-1, a DNA-based IL-12 immunotherapy in development for advanced ovarian cancer, and ThermoDox, a heat-activated liposomal doxorubicin candidate. The company also described early-stage nucleic-acid delivery platforms and a newly announced PLACCINE DNA vaccine initiative. It stated that it did not expect product-sale revenue for the foreseeable future.
Financial results and liquidity
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Technology development and licensing revenue | $0.5 million | $0.5 million |
| Research and development expense | $11.3 million | $13.1 million |
| General and administrative expense | $7.6 million | $8.0 million |
| Net loss | $21.5 million | $16.9 million |
| Net loss per share | $0.67 | $0.77 |
| Net cash used in operating activities | $15.6 million | $20.3 million |
The $0.5 million annual revenue was amortization of a prior $5 million Hisun technology-development payment, not product sales. Gross margin is not a meaningful disclosed operating measure for this development-stage business. The filing reports no product revenue.
At December 31, 2020, cash and cash equivalents were $17.2 million, total current assets were $18.8 million, current liabilities were $6.8 million, and working capital was $12.0 million. Cash increased from $6.9 million at year-end 2019. The company reported $5.1 million of notes payable, net of financing costs, and a $7.0 million EGEN earn-out liability. Debt was secured by substantially all assets other than intellectual property; the remaining loan carried a minimum interest rate of 9.625% and included a $2.5 million minimum-liquidity covenant.
Management said that, including approximately $43 million of first-quarter 2021 gross equity proceeds and expected net proceeds of approximately $1.85 million from sale of New Jersey tax losses, available resources were expected to fund operations through 2023. This estimate depends on assumptions and continued access to capital. The filing reports no off-balance-sheet financing arrangements.
Material changes and unusual items
- Net loss increased by $4.6 million year over year, despite lower R&D and G&A spending. Important non-cash items included a $2.4 million write-off of the remaining glioblastoma-related in-process R&D asset and a $1.3 million charge from remeasuring the EGEN earn-out liability. In 2019, the earn-out remeasurement had produced a $3.2 million gain.
- Operating cash use declined by $4.6 million year over year. Financing activities provided $18.0 million in 2020, including $22.8 million net proceeds from equity issuance; Celsion also repaid $5.0 million of loan principal and related end-of-term charges.
- The company repaid $5 million of its original $10 million Horizon loan in August 2020 and restructured the remaining $5 million. At year-end, the balance sheet showed $1.1 million current and $3.9 million non-current notes payable, net of financing costs.
- Common shares outstanding rose from 23.3 million at year-end 2019 to 40.7 million at year-end 2020. After subsequent financing, 75.0 million shares were outstanding as of March 18, 2021.
Programs, outlook, risks, and contingencies
- ThermoDox / OPTIMA: In July 2020, the independent monitoring committee found the Phase III trial had crossed its prespecified futility boundary (0.903 versus 0.900), though no safety concern was identified. Celsion later stopped follow-up after independent CRO and NIH analyses found no basis to continue. In February 2021, the company reported that OPTIMA had not met its primary overall-survival endpoint; the 556-patient database was frozen at 185 deaths. Management did not plan to pursue retrospective subgroup findings as a regulatory path.
- GEN-1 / OVATION 2: The randomized Phase II study was underway, with enrollment targeted at up to 110 patients. In February 2021, the company reported 34 patients enrolled and preliminary R0 resection rates of 80% in the GEN-1 arm (12 of 15 patients) and 58% in the control arm (7 of 12). These are interim, small-sample results; the primary endpoint is progression-free survival. The FDA granted GEN-1 Fast Track designation in February 2021. Earlier OVATION I results were from a small, non-randomized study and should not be treated as confirmatory evidence.
- PLACCINE: A provisional patent application was filed in January 2021 for a proposed DNA vaccine platform, including a possible COVID-19 vaccine. The filing describes preliminary research and proposed advantages, not demonstrated clinical efficacy or an active clinical-stage vaccine program.
- Key risks: The company had a history of substantial losses, an accumulated deficit of $312 million, no product revenue, and a continued need for capital that could dilute shareholders. Clinical success and regulatory approval are uncertain; patient enrollment, COVID-19 effects, third-party trial and manufacturing reliance, intellectual-property protection, reimbursement, and competition are additional risks.
- Legal matters: A 2019 shareholder action was settled in 2020, including $187,500 in plaintiff legal fees and repricing of certain options; the company denied wrongdoing. A securities class action filed in October 2020 and a derivative suit filed in February 2021 remained pending. The filing states that likelihood and potential loss could not be determined for the pending matters.
- The financial statements received an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2020; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the registrant identity: this source is a Celsion Corporation 10-K, despite the request naming Imunon, Inc.
- Review the full audited statements and debt note for debt maturities, covenant compliance, and cash runway assumptions.
- Track OVATION 2 enrollment, interim disclosures, and the prespecified progression-free-survival analysis; distinguish exploratory surgical outcomes from the primary endpoint.
- Verify the effects of first-quarter 2021 equity issuance on share count, dilution, and subsequent liquidity.
- Monitor the pending ThermoDox-related litigation and any new loss estimates or material developments.